Cost-effectiveness analysis of irinotecan plus fluorouracil/folinic acid compared with fluorouracil/folinic acid alone as first-line treatment for advanced colorectal cancer

W.M. Hart1, Carlos Rubio-Terrés2, Linda Pronk3, Svetlana Kobina4, Eduardo Díaz Rubio5
1EcoSta Consulting Group, S.L. Madrid, Spain
2HERO Consulting, C/Virgen de Aránzazu, 21, 28034, Madrid, Spain
3Scientific Department, Aventis Pharma, S.A. Madrid, Spain
4Health Economics and Outcomes Research, Aventis Pharma, Bridgewater, NJ, USA
5Oncology Department, Hospital Clínico San Carlos, Madrid, Spain

Tóm tắt

Từ khóa


Tài liệu tham khảo

Wingo PA, Tons T, Bolden S, et al. Cancer statistic, 1995. CA Cancer J Clin 1995;45:8–30.

Cáncer en España. Madrid: Ministerio de Sanidad y Consumo, 1993.

Regidor E, Rodríguez C, Gutierrez F, et al. Indicadores de salud. Tercera evaluación en España del programa regional europeo. Salud paratodos. Madrid: Ministerio de Sanidad y Consumo, 1995.

Cancer incidence in five continnents. Vol IV, V, VI, y VII (1982, 1987, 1992, 1995 y 1997). IARC Scientifics publications, No 42, 88,107,120,132.

Pommier Y, Tanizawa A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. En: Liu LF, editor. Advances in Pharmacology. New York: Academic Press, 1994;29B:73–92.

Midgley R, Kerr D. Colorectal cancer. Lancet 1999;353: 391–9.

Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–8.

Rougier P, Van Custem E, Bajetta E, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407–12.

Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil campared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–7.

Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905–14.

Consejo general de colegios oficiales de farmacéuticos de España. Catalogue of Pharmaceutical Specialties, Madrid: 2001.

Gisbert R, Brosa M. Base de datos de costes sanitarios. Versión 1.1c. Barcelona: Soikos, 2001.

Cunningham D, Falk S, Jackson DL. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer 2002;86:1677–83.

Montero MC, Valdivia ML, Carvajal E, et al. Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm Worls Sci 1994;16(4):187–92.

Schmitt C, Levy-Piedbois C, Frappé M, et al. Cost-effectiveness analysis of irinotecan+5FU/FA as first-line therapy in advanced colorectal cancer. Annals of Oncology 2000: 11(Suppl. 4):47.

Plans-Rubió P. Cost-effectiveness of pharmacologic treatments for the reduction of blood lipids. Med Clin (Barc) 1995;105:327–33.

Plans-Rubió P. Cost-effectiveness of cardiovascular prevention programs in Spain. Int J Technol Assess Health Care 1998;14:320–30.